Imatinib and beyond—the new CML study IVA randomized controlled comparison of imatinib vs imatinib/interferon-alpha vs imatinib/low-dose AraC vs imatinib after interferon-alpha failure in newly diagnosed chronic phase chronic myeloid leukemia

被引：0
|
作者：
U. Berger
G. Engelich
A. Reiter
A. Hochhaus
R. Hehlmann
机构：
[1] Universität Heidelberg,III. Medizinische Universitätsklinik, Klinikum Mannheim
来源：
Annals of Hematology | 2004年 / 83卷
关键词：
Chronic myeloid leukemia; Clinical trial; Imatinib; Interferon alpha; Stem cell transplantation;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：258 / 264
页数：6
相关论文
共 50 条
  • [31] Quality of life outcomes for CML patients on interferon-alpha plus Ara-C vs. imatinib after 24 months in the IRIS study.
    Hahn, EA
    Glendenning, GA
    Sorensen, MV
    Hudgens, SA
    Cella, D
    BLOOD, 2003, 102 (11) : 906A - 906A
  • [32] Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study
    Jorge E. Cortes
    Qian Jiang
    Jianxiang Wang
    Jianyu Weng
    Huanling Zhu
    Xiaoli Liu
    Andreas Hochhaus
    Dong-Wook Kim
    Jerald Radich
    Michael Savona
    Patricia Martin-Regueira
    Oumar Sy
    Renuka Gurnani
    Giuseppe Saglio
    Leukemia, 2020, 34 : 2064 - 2073
  • [33] Cardiac, Vascular and Hypertension Safety of Bosutinib vs Imatinib for Newly Diagnosed Chronic Myeloid Leukemia in the BFORE Trial
    Cortes, Jorge E.
    Bruemmendorf, Tim H.
    Gambacorti-Passerini, Carlo
    Clark, Richard
    Leip, Eric
    Viqueira, Andrea
    Kota, Vamsi
    Deininger, Michael
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S294 - S295
  • [34] fficacy and Safety of Bosutinib Vs Imatinib By Charlson Comorbidity Index in Newly Diagnosed Patients with Chronic Myeloid Leukemia
    Deininger, Michael W.
    Brummendorf, Tim H.
    Lipton, Jeffrey H.
    Milojkovic, Dragana
    Stenke, Leif
    Leip, Eric
    Purcell, Simon
    Viqueira, Andrea
    Cortes, Jorge E.
    BLOOD, 2022, 140 : 3913 - 3915
  • [35] Cost-effectiveness of imatinib versus interferon-α plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia
    Reed, SD
    Anstrom, KJ
    Ludmer, JA
    Glendenning, GA
    Schulman, KA
    CANCER, 2004, 101 (11) : 2574 - 2583
  • [36] Dasatinib or High-dose Imatinib for Chronic-phase Chronic Myeloid Leukemia After Failure of First-line Imatinib: a Randomized Phase 2 Trial
    Bajpai, Jyoti
    INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2008, 29 (04) : 24 - 27
  • [37] Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: A randomized phase 2 trial
    Kantarjian, Hagop
    Pasquini, Ricardo
    Hamerschlak, Nelson
    Rousselot, Philippe
    Holowiecki, Jerzy
    Jootar, Saengsuree
    Robak, Tadeusz
    Khoroshko, Nina
    Masszi, Tamas
    Skotnicki, Aleksander
    Hellmann, Andrzej
    Zaritsky, Andrey
    Golenkov, Anatoly
    Radich, Jerald
    Hughes, Timothy
    Countouriotis, Athena
    Shah, Neil
    BLOOD, 2007, 109 (12) : 5143 - 5150
  • [38] Phase I study of lonafarnib (SCH66336) in combination with imatinib for patients (pts) with chronic myeloid leukemia (CML) after failure to imatinib.
    Cortes, J
    O'Brien, S
    Verstovsek, S
    Daley, G
    Koller, C
    Ferrajoli, A
    Pate, O
    Faderl, S
    Ravandi-Kashani, F
    Talpaz, M
    Zhu, YL
    Statkevich, P
    Sugrue, M
    Kantarjian, H
    BLOOD, 2004, 104 (11) : 288A - 288A
  • [39] To assess the response and toxicity of imatinib mesylate and low-dose cytarabine in imatinib non-responder chronic myeloid leukemia, chronic phase (CML-CP) patients: A pilot study
    Singh, N.
    Kumar, L.
    Kochupillae, V.
    Raina, V.
    Sharma, A.
    Velpandian, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [40] Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: Results from the IRIS study
    Hahn, EA
    Glendenning, GA
    Sorensen, MV
    Hudgens, SA
    Druker, BJ
    Larson, RA
    O'Brien, SG
    Dobrez, DG
    Hensley, ML
    Cella, D
    JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (11) : 2138 - 2146
12345